ClearMed
BriefingsDrug & Biomarker IndexSaved (0)
All Oncology BriefingsNature Medicine
OncologyReal-World Cohort4 min read

Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

Association with clinical outcomes was assessed.

Published in Nature MedicineObservational cohort study
3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Source

Study Cohort

n = 115

Progression-free survival was longer in Dato-DXd-treated (median 7.2 versus 4.0 months; 0.40, 95% confidence interval 0.25-0.64) but not docetaxel-treated (median 4.1 versus 4.4 months; 0.94, 95% confidence interval 0.59-1.49) patients with TROP2 NMR-positive versus TROP2 NMR-negative samples (treatment by status interaction P = 0.0098), indicating that TROP2 NMR may be a predictive (measurable biological signal) for Dato-DXd.

What Changes?

Oncology · Real-World Cohort

Current Standard

Conventional oncology practice relies on standard-of-care monitoring and existing regimens prior to this study.

New Finding

The TROP2 NMR cut-point was optimized and validated in patients with nonsquamous NSCLC without actionable genomic alterations (primary intended-use population, n = 221) in the (measurable biological signal)-evaluable population (n = 352) of the TROPION-Lung01 trial.

3 Key Takeaways

Plain English Summary
  1. 01Core Finding

    However, TROP2 expression by pathologist assessment using conventional immunohistochemistry with visual scoring does not predict response to TROP2-directed antibody-drug conjugates in NSCLC.

  2. 02Study Evidence

    Tested in a study (n = 115) at the real-world stage.

  3. 03Practical Meaning

    findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.

What This Means for You

The TROP2 NMR cut-point was optimized and validated in patients with nonsquamous NSCLC without actionable genomic alterations (primary intended-use population, n = 221) in the (measurable biological signal)-evaluable population (n = 352) of the TROPION-Lung01 trial. Association with clinical outcomes was assessed. Progression-free survival was longer in Dato-DXd-treated (median 7.2 versus 4.0 months; 0.40, 95% confidence interval 0.25-0.64) but not docetaxel-treated (median 4.1 versus 4.4 months; 0.94, 95% confidence interval 0.59-1.49) patients with TROP2 NMR-positive versus TROP2 NMR-negative samples (treatment by status interaction P = 0.0098), indicating that TROP2 NMR may be a predictive for Dato-DXd.

The Discovery

Datopotamab deruxtecan (Dato-DXd)-a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate-has demonstrated (real-world effectiveness in the trial) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) ± actionable genomic alterations. However, TROP2 expression by pathologist assessment using conventional immunohistochemistry with visual scoring does not predict response to TROP2-directed antibody-drug conjugates in NSCLC. We developed TROP2 quantitative continuous scoring (QCS)-a fully supervised computational pathology approach that quantifies TROP2 expression in individual NSCLC cells and subcellular components from immunohistochemistry-stained slides. Using QCS to determine TROP2 expression at the tumor cell membrane and cytoplasm, normalized membrane ratio (NMR) was developed (ratio of membrane relative to membrane + cytoplasmic TROP2) in the (measurable biological signal)-evaluable population of patients with advanced NSCLC in the TROPION-PanTumor01 study (n = 115). The TROP2 NMR cut-point was optimized and validated in patients with nonsquamous NSCLC without actionable genomic alterations (primary intended-use population, n = 221) in the -evaluable population (n = 352) of the TROPION-Lung01 trial.

How It Works, Simply

This oncology research focuses on antibodies · Immune response · Blood (measurable biological signal). Researchers evaluated it using an observational cohort study (n = 115) at the real-world cohort stage of medical research.

3 Key Takeaways

Clinical Takeaways
  1. 01Core Finding

    However, TROP2 expression by pathologist assessment using conventional immunohistochemistry with visual scoring does not predict response to TROP2-directed antibody-drug conjugates in NSCLC.

  2. 02Study Evidence

    Tested in a study (n = 115) at the real-world stage.

  3. 03Practical Meaning

    findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.

01

Biological Mechanism & Study Design

Study Design & Cohort

Observational cohort study

Observational cohort study (n = 115) · Real-World Cohort

Biological Pathway & Modality

Antibodies · Immune response · Blood

Intervention: Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with

02

Experimental Findings & Endpoints

Datopotamab deruxtecan (Dato-DXd)-a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate-has demonstrated in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) ± actionable genomic alterations.

However, TROP2 expression by pathologist assessment using conventional immunohistochemistry with visual scoring does not predict response to TROP2-directed antibody-drug conjugates in NSCLC. We developed TROP2 quantitative continuous scoring (QCS)-a fully supervised computational pathology approach that quantifies TROP2 expression in individual NSCLC cells and subcellular components from immunohistochemistry-stained slides.

Using QCS to determine TROP2 expression at the tumor cell membrane and cytoplasm, normalized membrane ratio (NMR) was developed (ratio of membrane relative to membrane + cytoplasmic TROP2) in the -evaluable population of patients with advanced NSCLC in the TROPION-PanTumor01 study (n = 115). The TROP2 NMR cut-point was optimized and validated in patients with nonsquamous NSCLC without actionable genomic alterations (primary intended-use population, n = 221) in the -evaluable population (n = 352) of the TROPION-Lung01 trial.

03

Clinical Translation & Practice Context

The TROP2 NMR cut-point was optimized and validated in patients with nonsquamous NSCLC without actionable genomic alterations (primary intended-use population, n = 221) in the -evaluable population (n = 352) of the TROPION-Lung01 trial.

Association with clinical outcomes was assessed. Progression-free survival was longer in Dato-DXd-treated (median 7.2 versus 4.0 months; 0.40, 95% confidence interval 0.25-0.64) but not docetaxel-treated (median 4.1 versus 4.4 months; 0.94, 95% confidence interval 0.59-1.49) patients with TROP2 NMR-positive versus TROP2 NMR-negative samples (treatment by status interaction P = 0.0098), indicating that TROP2 NMR may be a predictive for Dato-DXd.

03

The Bottom Line · Clinical Pearl

“Progression-free survival was longer in Dato-DXd-treated (median 7.2 versus 4.0 months; hazard ratio 0.40, 95% confidence interval 0.25-0.64) but not docetaxel-treated (median 4.1 versus 4.4 months; hazard ratio 0.94, 95% confidence interval 0.59-1.49) patients with TROP2 NMR-positive versus TROP2 NMR-negative samples (treatment by biomarker status interaction P = 0.0098), indicating that TROP2 NMR may be a predictive biomarker for Dato-DXd.”

Published in Nature Medicine · Current Stage: Real-World Cohort

Practical Next Step

Questions for Your Next Doctor Visit

  1. 1Based on my health history, do these oncology findings (patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) ±) apply to my situation?
  2. 2How do the potential benefits of this approach compare with the standard care I'm currently using?
  3. 3Given the study's key limitation (observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.), what risks or follow-up steps should we watch for?
Oncology · Real-World Cohort
Study Type
Observational cohort study

Observational cohort study (n = 115)

Evidence Score
3/5 · Real-World Observation
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Who It Applies To
Patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) ±
Intervention & Mechanism
Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with

Antibodies · Immune response · Blood biomarker (measurable biological signal)

Key Limitation
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.

Translational Stage

LEVEL 2 · Real-World Cohort

Classified as Observational cohort study along the clinical evidence continuum

  1. Lab & Discovery
  2. Early Trials
  3. Human Evidence
  4. 4Real-World CohortActive

Indexed Clinical Entities

Monoclonal Antibodies & Biologics

Original Publication & AMA Citation

Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer. Nature Medicine. Published 2026;Nov 11. Accessed November 15, 2026. https://pubmed.ncbi.nlm.nih.gov/43015400/

Nature Medicine

https://pubmed.ncbi.nlm.nih.gov/43015400/

Read Original Paper

Continue Reading

Related in Oncology

View all Oncology briefings →
ONCOLOGY · CLINICAL PRACTICE

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial

In this interim analysis, short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival in patients with locally advanced rectal cancer, with a safety profile similar to long-course chemoradiotherapy followed by CAPOX. Comparison of this promising new treatment strategy with contemporary total neoadjuvant therapy strategies is warranted.

5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Oncology
ONCOLOGY · REAL-WORLD COHORT

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations

This guideline provides a practical framework for standardisation of clinical management of de novo metastatic nasopharyngeal carcinoma and identification of key evidence gaps for future research. We recommend that curative-intent treatment should be offered to medically fit patients with no more than three metastatic lesions in two or fewer organs at baseline or following response to systemic therapy; multimodality treatment (comprising immunochemotherapy, locoregional radiotherapy, metastasis-directed therapy, and maintenance therapy) is recommended.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Oncology
ONCOLOGY · REAL-WORLD COHORT

Development of the Children's Oncology Group long-term follow-up guideline for cancer genetics evaluation in childhood cancer survivors

Raising awareness of this guideline is crucial to enhancing the integration of genetics into survivorship care and improving health outcomes for childhood cancer survivors with CPS. This Policy Review details the importance, development, and anticipated impact of this new guideline.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Oncology